Cancer Targeted Technology
14241 NE Woodinville-Duvall Road #143
Woodinville
WA
98072-8564
United States
5 articles about Cancer Targeted Technology
-
NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403
8/7/2020
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research (SBIR) Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial. The clinical trial, conducted at University of California, San Francis
-
Cancer Targeted Technology Commences Phase I Clinical Trial in Prostate Cancer Patients with an Innovative Radiotherapy, CTT1403, and Receives a $3.2M NIH Grant to Fund the Trial
7/16/2019
The clinical trial is being conducted at University of California, San Francisco in collaboration with Dr. Rahul Aggarwal as Principal Investigator.
-
Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
11/6/2018
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced today that it filed an Investigational New Drug Application (IND) with the FDA to move forward a radiotherapeutic drug, CTT1403, into human clinical trials for prostate cancer.
-
Cancer Targeted Technology Receives an SBIR Grant and Announces Expansion of Its Pipeline
10/23/2018
Small Business Innovation Research (SBIR) grant to develop CTT1700, a unique prodrug targeted at men with prostate cancer that express Prostate Specific Membrane Antigen (PSMA).
-
Advanced Accelerator Applications Signs Exclusive License Agreement With Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
2/12/2018
The terms of the agreement include an upfront licensing fee, as well as certain milestone and royalty payments.